HCW Biologics ( (HCWB) ) just unveiled an update.
On March 31, 2025, HCW Biologics’ stockholders approved a 1-for-40 reverse stock split of its common stock, which was subsequently authorized by the Board of Directors. This move, effective April 11, 2025, aims to increase the stock’s per-share bid price above $1.00 to regain compliance with Nasdaq’s listing requirements. The reverse stock split will reduce the number of outstanding shares from approximately 44.9 million to about 1.1 million, without altering the total number of authorized shares. The adjustment will affect all stockholders uniformly, with fractional shares being rounded up to the nearest whole share. The company’s operations and stakeholder interests remain largely unchanged, aside from the necessary adjustments to stock options and warrants.
More about HCW Biologics
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies aimed at extending health span by addressing the link between chronic inflammation and age-related diseases, including cancer, cardiovascular, diabetes, neurodegenerative, and autoimmune diseases. The company utilizes advanced protein engineering to create multi-functional fusion molecules through its TOBI and TRBC drug discovery platforms.
YTD Price Performance: -37.33%
Average Trading Volume: 6,208,639
Technical Sentiment Signal: Buy
Current Market Cap: $12.68M
For a thorough assessment of HCWB stock, go to TipRanks’ Stock Analysis page.